glp-1 receptor agonist drugs in development research Frontiers Understanding GLP-1 receptor agonists and

These one-page guides will answer your patient's most common questions when starting a GLP-1 RA or SGLT2i medication..

Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity

not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH

Here's what experts think.